Shingrix Orders Limited by Manufacturer
June 21, 2018 – GlaxoSmithKline has implemented order limits on Shingrix (recombinant zoster vaccine) due to high demand.
The CDC’s website for current vaccine shortages and delays indicates that these order limits have led to shipping delays. Delays are expected to last through the remainder of 2018. GlaxoSmithKline plans to release doses on a consistent schedule, and the CDC expects this supply will allow the vaccination of more patients in 2018 than in 2017.
High demand may be due to the improved efficacy of Shingrix versus competitor Zostavax® (zoster vaccine live), from Merck.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.